Avidity Biosciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Avidity Biosciences sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 1 currently recruiting 3 completed early-phase tilt upper quartile by trial count

Avidity Biosciences: 8 sponsored US clinical trials, 1 recruiting.

Avidity Biosciences sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myotonic Disorders, with 2 trials.

Upper-quartile sponsor footprint

Avidity Biosciences sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 3

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

NCT07038200
ACTIVE NOT RECRUITING Phase 2

Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT06547216
ACTIVE NOT RECRUITING Phase 3

Global Study of Del-desiran for the Treatment of DM1

NCT06411288
ACTIVE NOT RECRUITING Phase 2

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping

NCT06244082
ACTIVE NOT RECRUITING Phase 1

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT05747924
COMPLETED Phase 1

Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping

NCT05670730
COMPLETED Phase 2

Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients

NCT05479981
COMPLETED Phase 1

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

NCT05027269

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 2

Therapeutic Areas

Myotonic Disorders 2
Fascioscapulohumeral Muscular Dystrophy Type 2 2
Fascioscapulohumeral Muscular Dystrophy Type 1 2
FSHD2 2
FSHD1 2
Exon 44 2
FSHD 2
Myotonic Dystrophy 2
Fascioscapulohumeral Muscular Dystrophy 2
DM1 2

What is open in the Avidity Biosciences pipeline

1 recruiting of 8 indexed (13% open); 3 completed (38%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Myotonic Disorders (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Avidity Biosciences: open-pipeline peers nationwide

Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

Avidity Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%10%20%30%40% Total trials Recruiting share Avidity BiosciencesAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Addario Lung Cancer Medical InstituteAmerican UniversityAnnexonAnsun Biopharma
Avidity Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Avidity Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Avidity Biosciences page

8 registered trials is a research-attention snapshot, not an endorsement of Avidity Biosciences or any single study.

  • 1 of Avidity Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Myotonic Disorders is the condition Avidity Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myotonic Disorders trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Avidity Biosciences pipeline card: 8 registered trials from official public datasets.Report a data error.